GlobeNewswire Inc.··NaGeron to Share Pipeline Progress at Needham Conference as RYTELO® Gains Market Traction
Geron Corporation will discuss its commercial-stage telomerase inhibitor platform at the Needham Healthcare Conference on April 13, highlighting RYTELO® adoption and ongoing Phase 3 trials in myelofibrosis.
GERNclinical trialbiopharmaceutical